Aliases & Classifications for Neuropathy

MalaCards integrated aliases for Neuropathy:

Name: Neuropathy 12 6 15 39 17 71
Peripheral Neuropathy 12 71
Peripheral Neuropathies 15

Classifications:



External Ids:

Disease Ontology 12 DOID:870
NCIt 50 C4731
SNOMED-CT 67 42658009
ICD10 32 G62.9
UMLS 71 C0031117 C0442874

Summaries for Neuropathy

Disease Ontology : 12 A nervous system disease that is located in nerves or nerve cells.

MalaCards based summary : Neuropathy, also known as peripheral neuropathy, is related to neuropathy, hereditary, with liability to pressure palsies and neuropathy, congenital hypomyelinating, 1, autosomal recessive, and has symptoms including seizures, tremor and back pain. An important gene associated with Neuropathy is NEFL (Neurofilament Light), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Pregabalin and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include nerves, spinal cord and eye, and related phenotypes are behavior/neurological and cellular

Related Diseases for Neuropathy

Diseases in the Neuropathy family:

Autoimmune Neuropathy Hereditary Neuropathies

Diseases related to Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2741)
# Related Disease Score Top Affiliating Genes
1 neuropathy, hereditary, with liability to pressure palsies 33.7 SPTLC1 PMP22 NEFL MPZ MFN2 GJB1
2 neuropathy, congenital hypomyelinating, 1, autosomal recessive 33.7 SLC12A6 PMP22 PMP2 NEFL MPZ MFN2
3 sensory peripheral neuropathy 33.6 SPTLC1 SLC12A6 PMP22 MPZ MFN2 GJB1
4 hypertrophic neuropathy of dejerine-sottas 33.6 SPTLC1 PMP22 NEFL MPZ MFN2 GJB1
5 neuropathy, hereditary sensory and autonomic, type iia 33.6 WNK1 SPTLC1 SLC12A6 GDAP1
6 peripheral nervous system disease 33.5 SPTLC1 PMP22 PMP2 PEX6 NEFL MPZ
7 charcot-marie-tooth disease 33.4 WNK1 SPTLC1 SLC12A6 PMP22 PMP2 NEFL
8 charcot-marie-tooth disease and deafness 33.4 SPTLC1 SLC12A6 PMP22 PMP2 NEFL MPZ
9 charcot-marie-tooth disease, x-linked dominant, 1 33.4 SPTLC1 PMP22 NEFL MPZ MFN2 GJB1
10 charcot-marie-tooth disease, demyelinating, type 1a 33.3 SPTLC1 PMP22 PMP2 NEFL MPZ MFN2
11 charcot-marie-tooth disease, axonal, type 2e 33.3 SPTLC1 SLC12A6 PMP22 NEFL MPZ MFN2
12 charcot-marie-tooth disease, demyelinating, type 1b 33.2 PMP22 NEFL MPZ MFN2 GJB1 GDAP1
13 hereditary sensory neuropathy 33.2 WNK1 SPTLC1 MPZ
14 optic nerve disease 33.2 NEFL MFN2 GDAP1
15 hereditary neuropathies 33.2 PMP22 MPZ MFN2 LMNA GJB1
16 charcot-marie-tooth disease, axonal, type 2b 33.2 SPTLC1 NEFL MPZ MFN2 GJB1 GDAP1
17 giant axonal neuropathy 33.1 NEFL GAN
18 neuropathy, hereditary sensory and autonomic, type ia 33.1 WNK1 SPTLC1
19 hereditary motor and sensory neuropathy, type iic 33.1 NEFL MPZ MFN2 GJB1 GDAP1
20 charcot-marie-tooth disease, demyelinating, type 1c 33.1 PMP22 NEFL MPZ MFN2 GJB1 GDAP1
21 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 33.1 PMP22 MPZ GJB1
22 neuronopathy, distal hereditary motor, type va 33.0 MFN2 HARS1 GDAP1
23 polyneuropathy 33.0 PMP22 MPZ MFN2 GJB1 GDAP1
24 charcot-marie-tooth disease, axonal, type 2d 33.0 SPTLC1 PMP22 NEFL MPZ MFN2 GJB1
25 axonal neuropathy 32.9 PMP22 NEFL MFN2 LMNA GDAP1 GAN
26 autoimmune peripheral neuropathy 32.9 PMP2 MPZ GJB1
27 charcot-marie-tooth disease, type 4a 32.9 PMP2 MPZ MFN2 GJB1 GDAP1
28 charcot-marie-tooth disease, dominant intermediate a 32.9 MPZ GJB1 GDAP1
29 charcot-marie-tooth disease, type 4d 32.9 MPZ GJB1 GDAP1
30 charcot-marie-tooth disease, axonal, type 2a1 32.9 MPZ MFN2 GDAP1
31 charcot-marie-tooth disease, demyelinating, type 1d 32.9 PMP22 PMP2 MPZ GJB1 GDAP1
32 charcot-marie-tooth disease, type 4b2 32.9 NEFL MPZ GJB1 GDAP1
33 charcot-marie-tooth disease, axonal, type 2b2 32.8 NEFL MPZ MFN2 GDAP1
34 neuropathy, hereditary sensory and autonomic, type v 32.8 WNK1 SPTLC1
35 guillain-barre syndrome 32.8 PMP22 PMP2 MPZ
36 charcot-marie-tooth disease, x-linked recessive, 2 32.8 MPZ MFN2 GJB1
37 charcot-marie-tooth disease, axonal, type 2t 32.8 SLC12A6 GDAP1 GAN
38 charcot-marie-tooth disease, axonal, type 2w 32.8 MPZ HARS1 GJB1 GDAP1
39 motor peripheral neuropathy 32.8 SLC12A6 PMP22 MFN2
40 charcot-marie-tooth disease, axonal, type 2p 32.7 SLC12A6 GDAP1 GAN
41 nerve compression syndrome 32.7 PMP22 MPZ GJB1
42 charcot-marie-tooth disease, axonal, type 2j 32.7 NEFL MPZ GDAP1
43 charcot-marie-tooth disease, axonal, type 2f 32.7 NEFL MPZ MFN2 GJB1 GDAP1
44 charcot-marie-tooth disease, demyelinating, type 1f 32.7 NEFL MPZ GJB1 GDAP1
45 charcot-marie-tooth disease, axonal, type 2b1 32.7 MFN2 LMNA GDAP1
46 charcot-marie-tooth disease, type 4c 32.7 MPZ GJB1 GDAP1
47 charcot-marie-tooth disease, recessive intermediate a 32.6 MFN2 GDAP1
48 brachial plexus neuropathy 32.6 PMP22 MPZ GJB1
49 charcot-marie-tooth disease, axonal, type 2l 32.6 SPTLC1 NEFL MPZ MFN2 GDAP1
50 charcot-marie-tooth disease, dominant intermediate c 32.6 SPTLC1 MPZ GJB1 GDAP1

Graphical network of the top 20 diseases related to Neuropathy:



Diseases related to Neuropathy

Symptoms & Phenotypes for Neuropathy

UMLS symptoms related to Neuropathy:


seizures, tremor, back pain, headache, syncope, hemiparesis, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, neuralgia, neurologic symptoms, atypical facial pain

MGI Mouse Phenotypes related to Neuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 AIFM1 GAN GDAP1 GJB1 HFE LMNA
2 cellular MP:0005384 10.1 AIFM1 DIAPH3 GAN GDAP1 GJB1 GP1BA
3 growth/size/body region MP:0005378 10.03 AIFM1 DIAPH3 GAN GJB1 HFE IARS2
4 mortality/aging MP:0010768 9.97 AIFM1 DIAPH3 GAN GJB1 HFE IARS2
5 muscle MP:0005369 9.5 AIFM1 GAN LMNA MFN2 PMP22 SLC12A6
6 nervous system MP:0003631 9.5 AIFM1 DIAPH3 GAN GDAP1 GJB1 HFE

Drugs & Therapeutics for Neuropathy

Drugs for Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 454)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
4
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
5
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
6
Nortriptyline Approved Phase 4 72-69-5 4543
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
tannic acid Approved Phase 4 1401-55-4
9
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
10
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
11
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
12
4-Aminopyridine Approved Phase 4 504-24-5 1727
13
Levodopa Approved Phase 4 59-92-7 6047
14
Carbidopa Approved Phase 4 28860-95-9 34359
15
Sodium citrate Approved, Investigational Phase 4 68-04-2
16
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
17
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
18
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
19
Amitriptyline Approved Phase 4 50-48-6 2160
20
Memantine Approved, Investigational Phase 4 19982-08-2 4054
21
Topiramate Approved Phase 4 97240-79-4 5284627
22
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
23
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
24
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
25
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
26
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
27
Levetiracetam Approved Phase 4 102767-28-2 441341
28
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
29
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
30
Propranolol Approved, Investigational Phase 4 525-66-6 4946
31
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
32
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
33
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
34
Norepinephrine Approved Phase 4 51-41-2 439260
35
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
36
Tapentadol Approved Phase 4 175591-23-8 9838022
37
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
38
Donepezil Approved Phase 4 120014-06-4 3152
39
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
40
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
41
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
42
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
43 Narcotics Phase 4
44 Analgesics, Opioid Phase 4
45 Antipyretics Phase 4
46 Antioxidants Phase 4
47 Alpha-lipoic Acid Phase 4
48 Thioctic Acid Phase 4
49 Respiratory System Agents Phase 4
50 Vasodilator Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1098)
# Name Status NCT ID Phase Drugs
1 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
2 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
3 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
4 The Effects of Omega-3 Fatty Acids on Chemotherapy-induced Neuropathy and Inflammation in Patients With Breast Cancer Unknown status NCT01049295 Phase 4
5 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
6 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
7 A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
8 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
9 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
10 Clinical Outcomes for Diabetic Foot Ulcers Treated With Clostridial Collagenase (SANTYL®) Ointment or With a Comparator Product Containing Silver Completed NCT02581488 Phase 4
11 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
12 Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study Completed NCT01373983 Phase 4 Ziconotide
13 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
14 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
15 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
16 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
17 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
18 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
19 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
20 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
21 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
22 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
23 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
24 The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
25 Gabapentin as an Adjunct for Pain Management During Dilation and Evacuation: A Double-blind Randomized Controlled Trial Completed NCT03635905 Phase 4 Gabapentin;Placebo
26 Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4 dalfampridine;Placebo
27 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4 levodopa-carbidopa
28 Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Citicoline
29 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
30 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
31 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
32 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
33 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
34 Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain Completed NCT02074267 Phase 4 Carbatin;Neurontin
35 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
36 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
37 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
38 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
39 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
40 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
41 Efficacy of Pregabalin in Patients With Radicular Pain Completed NCT00908375 Phase 4 Pregabalin;Sugar Pill
42 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
43 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
44 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
45 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
46 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
47 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study Completed NCT02056366 Phase 4 α-lipoic acid
48 Phase IV Open Non Comparative Trial to Evaluate Efficacy and Safety of Tegretol® in Diabetes Neuropathy Pain. Completed NCT01089855 Phase 4 Carbamazepine
49 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
50 A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy. Completed NCT00903851 Phase 4 Lidoderm

Search NIH Clinical Center for Neuropathy

Genetic Tests for Neuropathy

Anatomical Context for Neuropathy

The Foundational Model of Anatomy Ontology organs/tissues related to Neuropathy:

19
Nerves

MalaCards organs/tissues related to Neuropathy:

40
Spinal Cord, Eye, Breast, Bone Marrow, Endothelial, Skin, Colon

Publications for Neuropathy

Articles related to Neuropathy:

(show top 50) (show all 40627)
# Title Authors PMID Year
1
Transplantation of engineered exosomes derived from bone marrow mesenchymal stromal cells ameliorate diabetic peripheral neuropathy under electrical stimulation. 61
33553812 2021
2
Prospects for the application of transcranial magnetic stimulation in diabetic neuropathy. 61
33229735 2021
3
The neuroprotective effect of oxytocin on vincristine-induced neurotoxicity in mice. 61
33429010 2021
4
Satellite glia as a critical component of diabetic neuropathy: Role of lipocalin-2 and pyruvate dehydrogenase kinase-2 axis in the dorsal root ganglion. 61
33251681 2021
5
Diabetic fibrosis. 61
33378699 2021
6
Neuropathy and primary headaches affect different subgroups of inflammatory bowel disease patients. 61
32671582 2021
7
Advances in imaging technologies for the assessment of peripheral neuropathies in rheumatoid arthritis. 61
33427917 2021
8
Tofacitinib and Risk of Peripheral Neuropathy? Experience of 2 Cases in Patients With Rheumatoid Arthritis. 61
30028803 2021
9
Genetic profile and clinical characteristics of Chinese patients with spinocerebellar ataxia type 2: A multicenter experience over 10 years. 61
33070405 2021
10
Dysthyroid optic neuropathy: evaluation and management. 61
32729049 2021
11
Effects of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Structural Equation Approach With the Theory of Unpleasant Symptoms. 61
31833921 2021
12
A case of IVIg responsive paraneoplastic SOX1 peripheral neuropathy in a male with breast carcinoma. 61
33508769 2021
13
Ultrasound examination predicts 6-month progression in carpal tunnel syndrome patients. 61
33098574 2021
14
Severity of Cardiovascular Autonomic Neuropathy Is a Predictor Associated With Major Adverse Cardiovascular Events in Adults With Type 2 Diabetes Mellitus: A 6-Year Follow-up Study. 61
33046397 2021
15
High-frequency thermal coagulation to treat middle cluneal nerve entrapment neuropathy. 61
32415488 2021
16
Long-standing Multifocal Motor Neuropathy Presenting With Delayed Clinical Features of Anti-Myelin-Associated Glycoprotein Neuropathy and Elevated Anti-Myelin-Associated Glycoprotein Antibody Titers. 61
33596002 2021
17
Esophageal Dysphagia and Recurrent Aspiration From Treatment-Induced Neuropathy of Diabetes in an Adult Patient With Type 1 Diabetes. 61
33046405 2021
18
Temporal evolution of nerve conduction study abnormalities in anti-myelin-associated glycoprotein neuropathy. 61
33290607 2021
19
In-shoe pressure thresholds for people with diabetes and neuropathy at risk of ulceration: A systematic review. 61
33280984 2021
20
Acute Axonal Motor Neuropathy With Completely Reversible Conduction Failure-Is It Really Axonal? 61
33595999 2021
21
Vertebral Ischemic Necrosis in Diabetic Lumbosacral Radiculoplexus Neuropathy. 61
33479158 2021
22
Clinical features of middle cluneal nerve entrapment neuropathy. 61
33404869 2021
23
Optic Neuropathy Due to Compression by an Ectatic Internal Carotid Artery Within the Orbital Apex. 61
32366760 2021
24
Spontaneous Globe Luxation-Induced Optic Neuropathy. 61
32108116 2021
25
Biotinidase deficiency is a rare, potentially treatable cause of peripheral neuropathy with or without optic neuropathy in adults. 61
33364171 2021
26
Patterns of Retinal Ganglion Cell Damage in Nonarteritic Anterior Ischemic Optic Neuropathy Assessed by Swept-Source Optical Coherence Tomography. 61
32868560 2021
27
Is Cataract Surgery a Risk for Developing Nonarteritic Anterior Ischemic Optic Neuropathy? 61
33587535 2021
28
Autoimmune Small Fiber Neuropathy Associated With Ehlers-Danlos Syndrome Treated With Intravenous Immunoglobulins. 61
33596000 2021
29
Increased peptidergic fibers as a potential cutaneous marker of pain in diabetic small fiber neuropathy. 61
32833793 2021
30
Identification of Perinatal Risk Factors for Auditory Neuropathy Spectrum Disorder. 61
32609896 2021
31
Reduced Myocardial Uptake of 123I-MIBG in Congenital Insensitivity to Pain With Anhidrosis. 61
33351513 2021
32
Social Deprivation and Incident Diabetes-Related Foot Disease in Patients With Type 2 Diabetes: A Population-Based Cohort Study. 61
33483358 2021
33
Compound XiongShao Capsule ameliorates streptozotocin-induced diabetic peripheral neuropathy in rats via inhibiting apoptosis, oxidative - nitrosative stress and advanced glycation end products. 61
33161027 2021
34
Restricted Diffusion in the Optic Nerve Head After Shock-Induced Anterior Ischemic Optic Neuropathy. 61
32028450 2021
35
Ipsilateral Recurrence of Optic Disc Drusen-Associated Anterior Ischemic Optic Neuropathy in a 15-Year-Old Boy. 61
32235222 2021
36
Finger drop sign as a new variant of acute motor axonal neuropathy. 61
33217007 2021
37
Predictive model of ischemic optic neuropathy in spinal fusion surgery using a longitudinal medical claims database. 61
33248270 2021
38
In the borderland of multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculopathy. 61
33074453 2021
39
No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter cohort of patients with neuropathy. 61
32868752 2021
40
Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. 61
33078247 2021
41
Motor axonal neuropathy associated with GNE mutations. 61
33094863 2021
42
Metabolic syndrome and peripheral neuropathy. 61
33098165 2021
43
Visual Outcome Improvement in Tacrolimus-Related Bilateral Optic Neuropathy. 61
31842149 2021
44
Sexual dimorphism in the contribution of neuroendocrine stress axes to oxaliplatin-induced painful peripheral neuropathy. 61
32947545 2021
45
What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey. 61
33210163 2021
46
Comprehensive Review of Topical Analgesics for Chronic Pain. 61
33534003 2021
47
Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine. 61
33205374 2021
48
Systemic lupus erythematosus may have an early effect on peripheral nerve function in patients without clinical or electrophysiological neuropathy: comparison with age- and gender-matched controls. 61
32488429 2021
49
Delayed diagnosis of rheumatoid arthritis in an elderly patient presenting with weakness and desolation. 61
33547118 2021
50
Association of Urinary N-Acetyl-β-D-Glucosaminidase with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Mellitus without Nephropathy. 61
33517614 2021

Variations for Neuropathy

ClinVar genetic disease variations for Neuropathy:

6 (show top 50) (show all 92)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu) SNV Pathogenic 156553 rs587783070 1:220316451-220316451 1:220143109-220143109
2 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr) SNV Pathogenic 804285 rs1131040 5:140057507-140057507 5:140677922-140677922
3 HARS1 NM_002109.6(HARS1):c.730delG Deletion Pathogenic 804286 rs1581505917 5:140057005-140057005 5:140677420-140677420
4 PEX6 NM_000287.4(PEX6):c.2356C>T (p.Arg786Trp) SNV Pathogenic 553552 rs267608239 6:42933788-42933788 6:42966050-42966050
5 PEX6 NM_000287.4(PEX6):c.371T>C (p.Leu124Pro) SNV Pathogenic 869197 6:42946518-42946518 6:42978780-42978780
6 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser) SNV Pathogenic 14029 rs28928910 8:24813966-24813966 8:24956452-24956452
7 HFE NM_000410.3(HFE):c.845G>A (p.Cys282Tyr) SNV Pathogenic 9 rs1800562 6:26093141-26093141 6:26092913-26092913
8 LMNA NM_170707.4(LMNA):c.344A>T (p.Glu115Val) SNV Likely pathogenic 200932 rs794728588 1:156085053-156085053 1:156115262-156115262
9 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser) SNV Likely pathogenic 14029 rs28928910 8:24813966-24813966 8:24956452-24956452
10 NGLY1 NM_018297.4(NGLY1):c.1533_1536del (p.Asn511fs) Deletion Likely pathogenic 548658 rs765211108 3:25770699-25770702 3:25729208-25729211
11 COX6A1 NM_004373.4(COX6A1):c.103+1G>C SNV Likely pathogenic 560368 rs377504835 12:120876033-120876033 12:120438230-120438230
12 CHRNG NM_005199.5(CHRNG):c.256C>T (p.Arg86Cys) SNV Likely pathogenic 397615 rs777219451 2:233405327-233405327 2:232540617-232540617
13 DNAJB5 NM_001135005.3(DNAJB5):c.43C>T (p.Pro15Ser) SNV Likely pathogenic 243086 rs774909609 9:34990670-34990670 9:34990673-34990673
14 PMP2 NM_002677.5(PMP2):c.128T>A (p.Ile43Asn) SNV Likely pathogenic 243087 rs879253869 8:82357170-82357170 8:81444935-81444935
15 SPTLC3 NM_018327.4(SPTLC3):c.448T>C (p.Trp150Arg) SNV Likely pathogenic 243088 rs755919784 20:13053048-13053048 20:13072400-13072400
16 MT-ND4 NC_012920.1:m.11896C>G SNV Uncertain significance 370054 rs1057516065 MT:11896-11896 MT:11896-11896
17 ABCA4 NM_000350.3(ABCA4):c.203C>T (p.Pro68Leu) SNV Uncertain significance 99113 rs62654397 1:94577093-94577093 1:94111537-94111537
18 MYH14 NM_001145809.2(MYH14):c.1945+6G>A SNV Uncertain significance 374064 rs1057518869 19:50756016-50756016 19:50252759-50252759
19 PNPLA6 NM_001166114.2(PNPLA6):c.1205C>T (p.Ser402Leu) SNV Uncertain significance 397619 rs372193709 19:7606906-7606906 19:7542020-7542020
20 SPTAN1 NM_001130438.3(SPTAN1):c.4039G>A (p.Asp1347Asn) SNV Uncertain significance 207286 rs574740801 9:131367749-131367749 9:128605470-128605470
21 DYSF NM_001130987.2(DYSF):c.1449G>A (p.Met483Ile) SNV Uncertain significance 288879 rs146064054 2:71762219-71762219 2:71535089-71535089
22 NEB NM_001271208.2(NEB):c.21902C>T (p.Pro7301Leu) SNV Uncertain significance 387835 rs367626762 2:152384038-152384038 2:151527524-151527524
23 MKS1 NM_001165927.1(MKS1):c.1577G>A (p.Arg526Gln) SNV Uncertain significance 397617 rs746283445 17:56283513-56283513 17:58206152-58206152
24 PRX NM_020956.2(PRX):c.*2540G>A SNV Uncertain significance 397620 rs369505684 19:40901924-40901924 19:40396017-40396017
25 KIFBP NM_015634.4(KIFBP):c.167_187dup (p.Asp56_Glu62dup) Duplication Uncertain significance 397616 rs767103634 10:70748746-70748747 10:68988990-68988991
26 SBF2-AS1 NM_030962.3(SBF2):c.5014_5016del (p.Lys1672del) Deletion Uncertain significance 397621 rs750958357 11:9809202-9809204 11:9787655-9787657
27 PHKA1 NM_002637.4(PHKA1):c.1272T>A (p.Asp424Glu) SNV Uncertain significance 397618 rs1060499719 X:71870292-71870292 X:72650442-72650442
28 NEB NM_001271208.2(NEB):c.16637G>A (p.Arg5546His) SNV Uncertain significance 257765 rs201111610 2:152435919-152435919 2:151579405-151579405
29 DNM2 NM_001005360.2(DNM2):c.190G>A (p.Val64Ile) SNV Uncertain significance 133978 rs144250390 19:10870442-10870442 19:10759766-10759766
30 FLRT1 NM_014067.4(MACROD1):c.517+33243C>G SNV Uncertain significance 461796 rs140274429 11:63885468-63885468 11:64117996-64117996
31 FLRT1 NM_014067.4(MACROD1):c.517+34934G>C SNV Uncertain significance 461801 rs139768227 11:63883777-63883777 11:64116305-64116305
32 FLRT1 NM_014067.4(MACROD1):c.517+33881C>T SNV Uncertain significance 565723 rs767022154 11:63884830-63884830 11:64117358-64117358
33 FLRT1 NM_014067.4(MACROD1):c.517+34196G>A SNV Uncertain significance 566239 rs776773158 11:63884515-63884515 11:64117043-64117043
34 FLRT1 NM_014067.4(MACROD1):c.517+33604C>A SNV Uncertain significance 566560 rs1395376914 11:63885107-63885107 11:64117635-64117635
35 FLRT1 NM_014067.4(MACROD1):c.517+33719C>T SNV Uncertain significance 568577 rs769032516 11:63884992-63884992 11:64117520-64117520
36 FLRT1 NM_014067.4(MACROD1):c.517+34898_517+34918del Deletion Uncertain significance 571356 rs1565240655 11:63883793-63883813 11:64116321-64116341
37 FLRT1 NM_014067.4(MACROD1):c.517+33243C>T SNV Uncertain significance 575806 rs140274429 11:63885468-63885468 11:64117996-64117996
38 FLRT1 NM_014067.4(MACROD1):c.517+34250T>A SNV Uncertain significance 577882 rs1565241569 11:63884461-63884461 11:64116989-64116989
39 FLRT1 NM_014067.4(MACROD1):c.517+34535G>A SNV Uncertain significance 579757 rs756250929 11:63884176-63884176 11:64116704-64116704
40 FLRT1 NM_014067.4(MACROD1):c.517+33906T>G SNV Uncertain significance 640772 rs1590933528 11:63884805-63884805 11:64117333-64117333
41 FLRT1 NM_014067.4(MACROD1):c.517+34305T>C SNV Uncertain significance 643512 rs1590932597 11:63884406-63884406 11:64116934-64116934
42 FLRT1 NM_014067.4(MACROD1):c.517+33198G>A SNV Uncertain significance 645543 rs375487485 11:63885513-63885513 11:64118041-64118041
43 FLRT1 NM_014067.4(MACROD1):c.517+34236G>A SNV Uncertain significance 647420 rs756527574 11:63884475-63884475 11:64117003-64117003
44 FLRT1 NM_014067.4(MACROD1):c.517+33328C>A SNV Uncertain significance 658157 rs1590934834 11:63885383-63885383 11:64117911-64117911
45 KIF24 Deletion Uncertain significance 243059 9:34280042-34296294 9:34280044-34296296
46 FLRT1 NM_014067.4(MACROD1):c.517+34761C>G SNV Uncertain significance 530933 rs777177875 11:63883950-63883950 11:64116478-64116478
47 FLRT1 NM_014067.4(MACROD1):c.517+33591C>T SNV Uncertain significance 530934 rs138289564 11:63885120-63885120 11:64117648-64117648
48 FLRT1 NM_014067.4(MACROD1):c.517+34449C>T SNV Uncertain significance 530935 rs148012979 11:63884262-63884262 11:64116790-64116790
49 FLRT1 NM_014067.4(MACROD1):c.517+33260C>A SNV Uncertain significance 530936 rs143309484 11:63885451-63885451 11:64117979-64117979
50 FLRT1 NM_014067.4(MACROD1):c.517+34743C>T SNV Uncertain significance 530937 rs770193280 11:63883968-63883968 11:64116496-64116496

Copy number variations for Neuropathy from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107544 17 15900000 22100000 Microdeletion Neuropathy
2 107574 17 16000000 22200000 Copy number Neuropathy
3 216423 6 92100000 98700000 Microdeletion EPHA7 Neuropathy

Expression for Neuropathy

Search GEO for disease gene expression data for Neuropathy.

Pathways for Neuropathy

Pathways related to Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 PMP22 MPZ GJB1

GO Terms for Neuropathy

Biological processes related to Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial fusion GO:0008053 8.62 MFN2 GDAP1

Sources for Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....